United States Biotechnology & Medical Research

Akebia Therapeutics Inc (AKBA)

Track

Over the past 90 days, Akebia Therapeutics Inc. saw limited insider activity, characterized by a net sell value of approximately $62,181. The primary transaction involved CFO Erik Ostrowski, who sold 56,019 shares in late June. This activity follows a period where the stock price declined by 10% since the last earnings report.
Ticker: AKBA Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Akebia Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 29 Jun 2026
Value US$4,036,685.61 | Price 391.03 | Shares 93,061 (-40.3%)
Proposed sale 29 Jun 2026
Value US$701,740.15 | Price 295.54 | Shares 31,119
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-01 2026-06-29 S Sale
Ostrowski Erik

SVP, CFO, CBO & Treasurer

Officer
93,061 -40.3%
391.03
US$4,036,686 		93,061 -40.3% 391.03 US$4,036,686
2026-06-29 2026-06-29 PrS Proposed sale
Ostrowski Erik

Officer

Officer
31,119
295.54
US$701,740 		31,119 295.54 US$701,740
2026-03-05 2026-03-04 B Purchase
3.7
Butler John P.

CEO and President

Executive Director
34,867 +35.9%
21.16
US$3,910,943 		34,867 +35.9% 21.16 US$3,910,943
2026-02-04 2026-02-02 PlS Planned sale
Malabre Richard C

SVP, Chief Accounting Officer

Officer
13,382 -4.3%
1.39
US$18,601 		13,382 -4.3% 1.39 US$18,601
2026-02-04 2026-02-02 PlS Planned sale
Grund Nicholas

Chief Commercial Officer

Officer
31,244 -5.3%
1.39
US$43,429 		31,244 -5.3% 1.39 US$43,429
2026-02-04 2026-02-02 PlS Planned sale
Rucci Carolyn M.

SVP, Chief Legal Officer

Officer
27,544 -4.5%
1.39
US$38,286 		27,544 -4.5% 1.39 US$38,286
2026-02-04 2026-02-02 PlS Planned sale
Rucci Carolyn M.

SVP, Chief Legal Officer

Officer
25,382 -4.0%
1.39
US$35,281 		25,382 -4.0% 1.39 US$35,281
2026-02-04 2026-02-02 PlS Planned sale
3.6
Burke Steven Keith

SVP, Chief Medical Officer

Officer
20,701 -2.1%
1.39
US$28,774 		20,701 -2.1% 1.39 US$28,774
2026-02-04 2026-02-02 PlS Planned sale
3.6
Burke Steven Keith

SVP, Chief Medical Officer

Officer
25,375 -2.6%
1.39
US$35,271 		25,375 -2.6% 1.39 US$35,271
2026-02-04 2026-02-02 PlS Planned sale
3.7
Butler John P.

CEO and President

Executive Director
83,689 -2.5%
1.39
US$116,328 		83,689 -2.5% 1.39 US$116,328
2026-02-04 2026-02-02 PlS Planned sale
3.7
Butler John P.

CEO and President

Executive Director
114,891 -3.5%
1.39
US$159,698 		114,891 -3.5% 1.39 US$159,698
2026-02-04 2026-02-02 PlS Planned sale
3.7
Butler John P.

CEO and President

Executive Director
96,065 -2.8%
1.39
US$133,530 		96,065 -2.8% 1.39 US$133,530
2026-02-04 2026-02-02 PlS Planned sale
Malabre Richard C

SVP, Chief Accounting Officer

Officer
13,382 -4.3%
1.39
US$18,601 		13,382 -4.3% 1.39 US$18,601
2026-02-04 2026-02-02 PlS Planned sale
Malabre Richard C

SVP, Chief Accounting Officer

Officer
36,142 -10.4%
1.39
US$50,237 		36,142 -10.4% 1.39 US$50,237
2026-02-04 2026-02-02 PlS Planned sale
Grund Nicholas

Chief Commercial Officer

Officer
31,244 -5.3%
1.39
US$43,429 		31,244 -5.3% 1.39 US$43,429
2026-02-04 2026-02-02 PlS Planned sale
Grund Nicholas

Chief Commercial Officer

Officer
53,585 -8.3%
1.39
US$74,483 		53,585 -8.3% 1.39 US$74,483
2026-02-04 2026-02-02 PlS Planned sale
Ostrowski Erik

SVP, CFO, CBO & Treasurer

Officer
34,951 -4.9%
1.39
US$48,582 		34,951 -4.9% 1.39 US$48,582
2026-02-04 2026-02-02 PlS Planned sale
Rucci Carolyn M.

SVP, Chief Legal Officer

Officer
27,544 -4.5%
1.39
US$38,286 		27,544 -4.5% 1.39 US$38,286
2026-02-04 2026-02-02 PlS Planned sale
Rucci Carolyn M.

SVP, Chief Legal Officer

Officer
25,382 -4.0%
1.39
US$35,281 		25,382 -4.0% 1.39 US$35,281
2026-02-04 2026-02-02 PlS Planned sale
Rucci Carolyn M.

SVP, Chief Legal Officer

Officer
16,846 -2.6%
1.39
US$23,416 		16,846 -2.6% 1.39 US$23,416
2026-02-04 2026-02-02 PlS Planned sale
3.6
Burke Steven Keith

SVP, Chief Medical Officer

Officer
20,701 -2.1%
1.39
US$28,774 		20,701 -2.1% 1.39 US$28,774
2026-02-04 2026-02-02 PlS Planned sale
3.6
Burke Steven Keith

SVP, Chief Medical Officer

Officer
25,375 -2.6%
1.39
US$35,271 		25,375 -2.6% 1.39 US$35,271
2026-02-04 2026-02-02 PlS Planned sale
3.6
Burke Steven Keith

SVP, Chief Medical Officer

Officer
21,582 -2.1%
1.39
US$29,999 		21,582 -2.1% 1.39 US$29,999
2026-02-04 2026-02-02 PlS Planned sale
3.7
Butler John P.

CEO and President

Executive Director
83,689 -2.5%
1.39
US$116,328 		83,689 -2.5% 1.39 US$116,328
2026-02-04 2026-02-02 PlS Planned sale
3.7
Butler John P.

CEO and President

Executive Director
114,891 -3.5%
1.39
US$159,698 		114,891 -3.5% 1.39 US$159,698
2026-02-04 2026-02-02 PlS Planned sale
3.7
Butler John P.

CEO and President

Executive Director
96,065 -2.8%
1.39
US$133,530 		96,065 -2.8% 1.39 US$133,530
2026-02-04 2026-02-02 PlS Planned sale
3.7
Butler John P.

CEO and President

Executive Director
46,660 -1.3%
1.39
US$64,857 		46,660 -1.3% 1.39 US$64,857
2026-02-02 2026-02-02 PrS Proposed sale
Ostrowski Erik

Officer

Officer
34,951
1.39
US$48,739 		34,951 1.39 US$48,739
2026-02-02 2026-02-02 PrS Proposed sale
Grund Nicholas

Officer

Officer
84,829
1.39
US$118,294 		84,829 1.39 US$118,294
2026-02-02 2026-02-02 PrS Proposed sale
3.6
Burke Steven Keith

Officer

Officer
67,658
1.39
US$94,349 		67,658 1.39 US$94,349
2026-02-02 2026-02-02 PrS Proposed sale
3.7
Butler John P.

Officer

Officer
341,305
1.39
US$475,950 		341,305 1.39 US$475,950
2026-02-02 2026-02-02 PrS Proposed sale
Rucci Carolyn M.

Officer

Officer
69,772
1.39
US$97,297 		69,772 1.39 US$97,297
2025-07-01 2025-06-30 PlS Planned sale
Ostrowski Erik

SVP, CFO, CBO & Treasurer

Officer
41,314 -7.6%
3.67
US$151,622 		41,314 -7.6% 3.67 US$151,622
2025-06-11 2025-06-09 PlS Planned sale
Malabre Richard C

SVP, Chief Accounting Officer

Officer
15,000 -5.3%
4.01
US$60,150 		15,000 -5.3% 4.01 US$60,150
2025-06-05 2025-06-04 PlS Planned sale
Malabre Richard C

SVP, Chief Accounting Officer

Officer
13,334 -4.8%
3.53
US$47,069 		13,334 -4.8% 3.53 US$47,069
2025-03-04 2025-03-03 PlS Planned sale
3.6
Burke Steven Keith

SVP, Chief Medical Officer

Officer
7,144 -0.9%
1.83
US$13,074 		7,144 -0.9% 1.83 US$13,074
2025-03-04 2025-03-03 PlS Planned sale
3.7
Butler John P.

CEO and President

Executive Director
46,409 -1.8%
1.83
US$84,928 		46,409 -1.8% 1.83 US$84,928
2025-03-03 2025-03-03 PrS Proposed sale
3.6
Burke Steven Keith

Officer

Officer
7,144
1.83
US$13,086 		7,144 1.83 US$13,086
2025-03-03 2025-03-03 PrS Proposed sale
3.7
Butler John P.

Officer; Director

Executive Director
46,409
1.83
US$85,007 		46,409 1.83 US$85,007
2025-02-04 2025-02-03 PlS Planned sale
3.6
Burke Steven Keith

SVP, Chief Medical Officer

Officer
27,236 -3.2%
2.10
US$57,196 		27,236 -3.2% 2.10 US$57,196
2025-02-04 2025-02-03 PlS Planned sale
3.6
Burke Steven Keith

SVP, Chief Medical Officer

Officer
23,270 -2.7%
2.10
US$48,867 		23,270 -2.7% 2.10 US$48,867
2025-02-04 2025-02-03 PlS Planned sale
Grund Nicholas

Chief Commercial Officer

Officer
55,621 -11.2%
2.10
US$116,804 		55,621 -11.2% 2.10 US$116,804
2025-02-04 2025-02-03 PlS Planned sale
Malabre Richard C

SVP, Chief Accounting Officer

Officer
30,202 -9.7%
2.10
US$63,424 		30,202 -9.7% 2.10 US$63,424
2025-02-04 2025-02-03 PlS Planned sale
3.7
Butler John P.

CEO and President

Executive Director
97,982 -3.6%
2.10
US$205,762 		97,982 -3.6% 2.10 US$205,762
2025-02-04 2025-02-03 PlS Planned sale
3.7
Butler John P.

CEO and President

Executive Director
46,268 -1.7%
2.10
US$97,163 		46,268 -1.7% 2.10 US$97,163
2025-02-03 2025-02-03 PrS Proposed sale
Grund Nicholas

Officer

Officer
55,621
2.10
US$117,060 		55,621 2.10 US$117,060
2025-02-03 2025-02-03 PrS Proposed sale
3.6
Burke Steven Keith

Officer

Officer
50,506
2.10
US$106,295 		50,506 2.10 US$106,295
2025-02-03 2025-02-03 PrS Proposed sale
3.7
Butler John P.

Officer; Director

Executive Director
144,250
2.10
US$303,589 		144,250 2.10 US$303,589
2024-05-14 2024-05-13 PlS Planned sale
3.5
Hadas Nicole R.

SVP, Chief Legal Officer

Officer
12,016 -1.8%
1.26
US$15,140 		12,016 -1.8% 1.26 US$15,140
2024-05-14 2024-05-13 PlS Planned sale
3.6
Dahan Michel

SVP, Chief Operating Officer

Officer
34,840 -4.9%
1.26
US$43,898 		34,840 -4.9% 1.26 US$43,898
2024-05-13 2024-05-13 PrS Proposed sale
3.6
Dahan Michel

Officer

Officer
34,840
1.26
US$43,818 		34,840 1.26 US$43,818
2024-05-13 2024-05-13 PrS Proposed sale
3.5
Hadas Nicole R.

Officer

Officer
12,016
1.26
US$15,113 		12,016 1.26 US$15,113
2024-03-01 2024-02-29 S Sale
3.6
Burke Steven Keith

SVP, Chief Medical Officer

Officer
7,169 -1.0%
1.58
US$11,327 		7,169 -1.0% 1.58 US$11,327
2024-03-01 2024-02-29 S Sale
3.5
Hadas Nicole R.

SVP, Chief Legal Officer

Officer
5,974 -0.9%
1.58
US$9,439 		5,974 -0.9% 1.58 US$9,439
2024-03-01 2024-02-29 S Sale
3.6
Dahan Michel

SVP, Chief Operating Officer

Officer
8,661 -1.2%
1.58
US$13,684 		8,661 -1.2% 1.58 US$13,684
2024-03-01 2024-02-29 S Sale
3.7
Butler John P.

CEO and President

Executive Director
46,570 -2.2%
1.58
US$73,581 		46,570 -2.2% 1.58 US$73,581
2024-02-29 2024-02-29 PrS Proposed sale
3.7
Butler John P.

Officer; Director

Executive Director
46,570
1.58
US$73,413 		46,570 1.58 US$73,413
2024-02-29 2024-02-29 PrS Proposed sale
3.6
Burke Steven Keith

Officer

Officer
7,169
1.58
US$11,301 		7,169 1.58 US$11,301
2024-02-29 2024-02-29 PrS Proposed sale
3.6
Dahan Michel

Officer

Officer
8,661
1.58
US$13,653 		8,661 1.58 US$13,653
2024-02-29 2024-02-29 PrS Proposed sale
3.5
Hadas Nicole R.

Officer

Officer
5,974
1.58
US$9,417 		5,974 1.58 US$9,417
2024-02-29 2024-02-27 PlS Planned sale
3.5
Hadas Nicole R.

SVP, Chief Legal Officer

Officer
7,411 -1.1%
1.52
US$11,265 		7,411 -1.1% 1.52 US$11,265
2024-02-29 2024-02-27 S Sale
3.7
Butler John P.

CEO and President

Executive Director
37,733 -1.8%
1.52
US$57,354 		37,733 -1.8% 1.52 US$57,354
2024-02-29 2024-02-27 S Sale
3.6
Dahan Michel

SVP, Chief Operating Officer

Officer
10,744 -1.5%
1.52
US$16,331 		10,744 -1.5% 1.52 US$16,331
2024-02-29 2024-02-27 PlS Planned sale
3.6
Burke Steven Keith

SVP, Chief Medical Officer

Officer
8,367 -1.2%
1.52
US$12,718 		8,367 -1.2% 1.52 US$12,718
2024-02-27 2024-02-27 PrS Proposed sale
3.5
Hadas Nicole R.

Officer

Officer
7,411
1.52
US$11,245 		7,411 1.52 US$11,245
2024-02-27 2024-02-27 PrS Proposed sale
3.6
Dahan Michel

Officer

Officer
10,744
1.52
US$16,302 		10,744 1.52 US$16,302
2024-02-27 2024-02-27 PrS Proposed sale
3.6
Burke Steven Keith

Officer

Officer
8,367
1.52
US$12,695 		8,367 1.52 US$12,695
2024-02-27 2024-02-27 PrS Proposed sale
3.7
Butler John P.

Officer; Director

Executive Director
37,733
1.52
US$57,252 		37,733 1.52 US$57,252
2024-02-02 2024-02-01 S Sale
3.6
Burke Steven Keith

SVP, Chief Medical Officer

Officer
24,311 -3.3%
1.68
US$40,842 		24,311 -3.3% 1.68 US$40,842
2024-02-02 2024-02-01 S Sale
3.7
Butler John P.

CEO and President

Executive Director
46,489 -2.1%
1.68
US$78,102 		46,489 -2.1% 1.68 US$78,102
2024-02-01 2024-02-01 PrS Proposed sale
3.7
Butler John P.

Officer; Director

Executive Director
46,489
1.68
US$77,957 		46,489 1.68 US$77,957
2024-02-01 2024-02-01 PrS Proposed sale
3.6
Burke Steven Keith

Officer

Officer
24,311
1.68
US$40,767 		24,311 1.68 US$40,767
2024-05-09 2023-08-25 S Sale
3.6
Burke Steven Keith

SVP, Chief Medical Officer

Officer
27,000 -3.9%
1.15
US$31,050 		27,000 -3.9% 1.15 US$31,050
2023-05-25 2023-05-25 PrS Proposed sale
3.5
Hadas Nicole R.

Officer

Officer
63,186
1.22
US$77,270 		63,186 1.22 US$77,270
2023-05-25 2023-05-25 PrS Proposed sale
3.6
Dahan Michel

Officer

Officer
95,478
1.22
US$116,760 		95,478 1.22 US$116,760
Explore more

More insider trading research around Akebia Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America